Squarepoint
MBRX icon

Squarepoint’s Moleculin Biotech MBRX Stock Holding History

Squarepoint’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-206
Closed -$44.7K – 4060
2023
Q2 		$44.7K Buy
206
+142
+222% +$37.5K ﹤0.01% 3450
2023
Q1 		$23K Buy
+64
New +$28K ﹤0.01% 3121
2021
Q2 		– Sell
-77
Closed -$118K – 3505
2021
Q1 		$118K Buy
77
+72
+1,440% +$132K ﹤0.01% 2863
2020
Q4 		$10K Buy
+5
New +$8.87K ﹤0.01% 2850
2020
Q3 		– Sell
-5
Closed -$11K – 2699
2020
Q2 		$11K Buy
+5
New +$11.9K ﹤0.01% 2162

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PJSIMP
P.J. Schmidt Investment Management (PJS) Cedarburg, Wisconsin $643M AUM 21.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Squarepoint's MBRX Position: Q3 2023 in Review

Squarepoint sold out of Moleculin Biotech (MBRX) in Q3 2023, closing a stake of 206 shares — an estimated $44.7K sold.

Squarepoint first reported a position in MBRX in Q2 2020 and held it in 5 quarters. The position peaked at $118K in Q1 2021. 19 funds tracked by Wall St. Rank hold MBRX as of Q3 2023.

  • Squarepoint reported no remaining Moleculin Biotech position as of Q3 2023 after selling out during the quarter.
  • Squarepoint sold 206 Moleculin Biotech shares in Q3 2023, an estimated $44.7K.
  • Squarepoint first reported a position in Moleculin Biotech in Q2 2020 and held it in 5 quarters.
  • Squarepoint's Moleculin Biotech position peaked at $118K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2023.

Based on Squarepoint's 13F filing for Q3 2023, filed 14 Nov 2023.